INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, C9
Completes Acquisition of Forte Biosciences, Inc.
ALKIVIA Study Topline Results August 17, 2026
Press Release August 3, 2026
Material disclosure
Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
To Host Autoimmune Myositis R&D Webinar
Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Annual and Transition Report of Foreign Private Issuers
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Tender Offer Statement by Third Party
Submission Upload
Correspondence